The Medicines Company declares positive results from Inclisiran trial
Category: #health  By Nikita Chaurasia  Date: 2019-08-28
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

The Medicines Company declares positive results from Inclisiran trial
  • The ORION-11 trial of inclisiran sodium 300 mg reached all secondary and primary endpoints with efficacy that is consistent with the findings from Phase 2 and 1 trials.
     
  • The trial evaluated that inclisiran was tolerated well and confirmed that its safety profile was as favorable as that shown in the ORION-3 and ORION-1 Phase 2 open-label extension studies.

The Medicines Company, a biopharmaceutical company dedicated to halt atherosclerosis progression and reduce cardiovascular risk, reportedly announced the positive topline outcomes of the first Phase 3 clinical trial examining the safety, tolerability and efficacy of inclisiran to reduce LDL-cholesterol by taking doses twice a year.

The ORION-11 trial of inclisiran sodium 300 mg reached all secondary and primary endpoints with efficacy that is consistent with findings from Phase 2 and 1 trials. The trial evaluated that inclisiran was tolerated well and confirmed that its safety profile was as favorable as that shown in the ORION-3 and ORION-1 Phase 2 open-label extension studies.

Detailed safety, tolerability and efficacy data from ORION-11 would be presented at a science session being conducted at the European Society of Cardiology’s ESC Congress 2019 in Paris on the 2nd of September at 8:30 am Central European Time (CET).

Mark Timney, CEO at The Medicines Company stated that it is an important occasion that strengthens the company’s confidence on in the immense potential of inclisiran to radically change cardiovascular disease treatment.

Mark added that he was proud of the company’s clinical development department’s commitment to quickly and efficiently develop this top-quality investigational therapy which could help millions of patients of ASCVD to attain treatment goals, have healthier lives and live longer.

This global study took place at 70 different sites across seven countries, ex-U.S. Each trial participant was given inclisiran sodium 300 mg, initially given as a subcutaneous injection, then again after three months and every six months after first three months.

 

Source Credit: https://www.themedicinescompany.com/investor/pr/3992694/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Nokia partners with LG Uplus to expand 5G coverage in South Korea

Nokia partners with LG Uplus to expand 5G coverage in South Korea

By Nikita Chaurasia

Finnish telecommunications giant Nokia Corporation has reportedly signed a joint venture agreement with LG Uplus, a prominent cellular carrier, to expand 5G coverage in South Korea. The duo intends to achieve this by deploying Nokia’s end-to-e...

Mercedes-Benz unveils the S-Class of EVs, comes with a 56-inch display

Mercedes-Benz unveils the S-Class of EVs, comes with a 56-inch display

By Nikita Chaurasia

Mercedes-Benz, a German multinational automaker of luxury and commercial vehicles, has unveiled its flagship electric sedan, the EQS. The new vehicle is likely to allow Mercedes to take on Tesla Inc., as the market for electric vehicles (EVs) continu...

Ford takes on GM, Tesla by debuting its first hands-free driving system

Ford takes on GM, Tesla by debuting its first hands-free driving system

By Nikita Chaurasia

Ford Motor Company, the American multinational automaker, is reportedly planning on introducing a hands-free driving feature on its 2021 Mustang Models as well as 2021 F-150 pickup truck through a software update, by the end of the year. The automob...